Metabolism of 7-benzyloxy-4-trifluoromethylcoumarin by human hepatic cytochrome P450 isoforms

References

• ANDERSSON, T., MINERS, J. 0., VERONESE, M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated both by S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131–137.
   Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• BUTERS, J. T. M., SCHILLER, C. D. and CHou, R. C., 1993, A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethylcoumarin. Biochemical Pharmacology, 46, 1577–1584.
   Google Scholar
• CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   Google Scholar
• CHAURET, N., TREMBLAY, N., LACKMAN, R. L., GAUTHIER, J.-Y., SILVA, J. M., MAROIS, J., YERGEY, J. A. and NICOLL-GRIFFITH, D. A., 1999, Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe. Analytical Biochemistry, 276, 215–226.
   Google Scholar
• CLARKE, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167–1202.
   PubMed Web of Science ®Google Scholar
• CLARKE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica, 24, 517–526.
   PubMed Web of Science ®Google Scholar
• CODE, E. L., CRESPI, C. L., PENMAN, B. W., GONZALEZ, F. J., CHANG, T. K. H. and WAXMAN, D. J., 1997, Human cytochrome P4502B6. Interindividual hepatic expression, substrate specificity, and role in precarcinogen activation. Drug Metabolism and Disposition, 25, 985–993.
   Google Scholar
• CRESPI, C. L., MILLER, V. P., ACKERMANN, J. M., STRESSER, D. M. and BUSBY, W. F., JR, 1999, Novel high throughput fluorescent cytochrome P450 assays. Toxicological Sciences, 48(1-S), 69.
   Google Scholar
• CRESPI, C. L., MILLER, V. P. and PENMAN, B. W., 1997, Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analytical Biochemistry, 248, 188–190.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L., MILLER, V. P. and PENMAN, B. W., 1998, High throughput screening for inhibition of cytochrome P450 metabolism. Medical Chemistry Research, 8, 457–471.
   Web of Science ®Google Scholar
• FUHR, U., DOEHMER, J., BATTULA, N., WoLFEL, C., KUDLA, C., KEITA, Y. and STAIB, A. H., 1992, Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochemical Pharmacology, 43, 225–235.
   PubMed Web of Science ®Google Scholar
• HEYN, H., WHITE, R. B. and STEVENS, J. C., 1996, Catalytic role of P4502B6 in the N-demethylation of S-mephenytoin. Drug Metabolism and Disposition, 24, 948–954.
   PubMed Web of Science ®Google Scholar
• KENNEDY, S. W. and JoNEs, S. P., 1994, Simultaneous measurement of cytochrome P4501A catalytic activity and total protein concentration with a fluorescent plate reader. Analytical Biochemistry, 222, 217–223.
   PubMed Web of Science ®Google Scholar
• LAKE, B. G., 1987, Preparation and characterisation of microsomal fractions for studies of xenobiotic metabolism. In K. Snell and B. Mullock (eds), Biochemical Toxicology: A Practical Approach (Oxford: IRL Press), pp. 183–215.
   Google Scholar
• LECOEUR, S., BONIERBALE, E., CHALLINE, D., GAUTER, J.-C., VALADON, P., DANSETTE, P. M., CATINOT, R., BALLET, F., MANSUY, D. and BEAUNE, P. H., 1994, Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chemical Research in Toxicology, 7, 434–442.
   Google Scholar
• LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J. 1951, Protein measurement with the Folin phenol reagent Journal of Biological Chemistry, 193, 265–275.
   Google Scholar
• MEI, Q., TANG, C., ASSANG, C., LIN, Y., SLAUGHTER, D., RODRIGUES, A. D., BAILLIE, T. A., RUSHMORE, T. H. and SHou, M., 1999, Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. Journal of Pharmacology and Experimental Therapeutics, 291, 749–759.
   PubMed Web of Science ®Google Scholar
• MINERS, J. 0. and BIRKETT, D. J., 1998, Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology, 45, 525–538.
   Google Scholar
• NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, 0., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetks, 6, 1–42.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P45 Os: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobioticia, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• PARKINSON, A., 1996a, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathology, 24, 45–57.
   Web of Science ®Google Scholar
• PARKINSON, A., 1996b, Biotransformation of xenobiotics. In C. D. Klaassen (ed.), Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th edn (New York: McGraw Hill), pp. 113–186.
   Google Scholar
• PEARCE, R. E., RODRIGUES, A. D., GOLDSTEIN, J. A. and PARKINSON, A., 1996, Identification of the human P450 enzymes involved in lansoprazole metabolism. Journal of Pharmacology and Experimental Therapeutics, 277, 805–816.
   PubMed Web of Science ®Google Scholar
• PELKONEN, 0., MÁENPÄÄ, J., TAAVITSAINEN, P., RAUTIO, A. and RAUNIO, H., 1998, Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica, 28, 1203–1253.
   Google Scholar
• RENWICK, A. B., MISTRY, H., BALL, S. E., WALTERS, D. G., KAO, J. and LAKE, B. G., 1998, Metabolism of zaleplon by human hepatic cytochrome P450 isoforms. Xenobiotica, 28, 337–348.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., 1999, Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver micros omes. Biochemical Pharmacology, 57, 465–480.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J., McMANus, M. E., TASSANEEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. 0., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767–1776.
   Google Scholar
• WRIGHTON, S. A., RING, B. J. and VANDENBRANDEN, M., 1995, The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicologic Pathology, 23, 199–208.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VANDENBRANDEN, M., 1993b, Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Archives of Biochemistry and Biophysics, 306, 240–245.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, LA., RING, B. J., RETTIE, A. E. and CASHMAN, J. R., 1993a, In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Reviews, 25, 453–484.
   PubMed Web of Science ®Google Scholar
• YANG, T. J., KRAUSZ, K. W., SAI, Y., GONZALEZ, F. J. and GELBOIN, H. V., 1999, Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism. Drug Metabolism and Disposition, 27, 102–109.
   PubMed Web of Science ®Google Scholar
• YASUMORI, T., NAGATA, K., YANG, S. K., CHEN, L.-S., MURAYAMA, N., YAMAZOE, Y. and KATO, R., 1993, Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmaco-genetics, 3, 291–301.
   Google Scholar